Valuation: Tengion, Inc.

Market Cap 110K 96.2K 88.92K 81.78K 154K 10.58M 157K 1.06M 417K 5.18M 412K 403K 17.84M P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 5.55M 4.87M 4.5M 4.14M 7.81M 535M 7.93M 53.78M 21.08M 262M 20.85M 20.39M 902M EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.70%+5.76%-35.11%-42.62% 640M
+26.99%+67.53%+249.66% - 515M
-3.22%-10.61%-43.82%+12.23% 114M
-2.50%-7.46%+14.23%+66.46% 108M
Average +5.40%+16.17%+46.24%+12.02% 344.15M
Weighted average by Cap. +9.79%+27.16%+74.49%-21.75%

Financials

2012 2013
Net sales - -
Net income -16.93M -14.84M -13.72M -12.61M -23.8M -1.63B -24.18M -164M -64.29M -799M -63.57M -62.18M -2.75B -18.93M -16.59M -15.33M -14.1M -26.61M -1.83B -27.04M -183M -71.88M -893M -71.07M -69.52M -3.08B
Net Debt 3.73M 3.27M 3.02M 2.78M 5.25M 360M 5.33M 36.16M 14.18M 176M 14.02M 13.71M 607M 5.44M 4.77M 4.41M 4.06M 7.65M 525M 7.77M 52.72M 20.67M 257M 20.43M 19.99M 885M
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
-